A Multi-Center, Single-Arm, Pilot Study of 5-FU Based Doublet Chemotherapy Plus Bevacizumab as Neoadjuvant Therapy for Patients With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer

Trial Profile

A Multi-Center, Single-Arm, Pilot Study of 5-FU Based Doublet Chemotherapy Plus Bevacizumab as Neoadjuvant Therapy for Patients With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 17 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 01 Jul 2015 Planned End Date changed from 1 Jul 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
    • 01 Jul 2015 Planned primary completion date changed from 1 Jul 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top